Gruppo Oncologico Italiano Di Ricerca Clinica

This study tests a new combination of the immunotherapy drug cemiplimab plus chemotherapy for people with advanced squamous non-small cell lung cancer who have not had prior treatment. The goal is to see if this approach helps patients live longer. About 108 adults will take part…

This study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (XELOX) after radiation therapy can improve outcomes for people with locally advanced rectal cancer. About 270 participants will be randomly assigned to receive either the combination or c…

This study tests whether the drug avelumab can help keep advanced bladder cancer from getting worse after initial chemotherapy. About 144 people who have already received two prior treatments will receive avelumab as a maintenance therapy. The main goal is to see how long the can…

This study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink or slow advanced kidney cancer in 108 adults whose cancer returned after prior pembrolizumab treatment. Participants receive the drug combination and are monitored for tumor response and side e…

This study looks at 150 adults aged 18-49 newly diagnosed with early-onset gastrointestinal cancer. Researchers will collect information on tumor features, lifestyle habits, and treatment outcomes over 12 months. The goal is to better understand this rising trend, not to test a n…